Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
37716828
DOI
10.1016/j.vaccine.2023.09.019
PII: S0264-410X(23)01089-7
Knihovny.cz E-resources
- Keywords
- Dogs, Tick-borne encephalitis, Vaccine,
- MeSH
- Immunization MeSH
- Encephalitis, Tick-Borne * prevention & control veterinary MeSH
- Humans MeSH
- Mice MeSH
- Antibodies, Viral MeSH
- Dogs MeSH
- Vaccination MeSH
- Viral Vaccines * MeSH
- Encephalitis Viruses, Tick-Borne * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antibodies, Viral MeSH
- Viral Vaccines * MeSH
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
References provided by Crossref.org
